Technology | July 07, 2015

Biosense Webster Launches Confidense Module for Optimized High-Density Mapping

Proprietary algorithm streamlines data collection, annotation and validation for company’s Carto System

Biosense Webster, Confidense Module, Carto, multi-electrode mapping, 3-D

Carto 3 System image courtesy of Biosense Webster

July 7, 2015 - Biosense Webster Inc. announced the launch of the Confidense Module, an innovative technology that streamlines the creation of real-time 3-D maps of a patient's cardiac structures during catheter ablation procedures. Utilizing an advanced, proprietary algorithm, the module enhances the process for validating information, or "points," acquired during multi-electrode mapping, enabling electrophysiologists to focus their time and expertise on the most relevant data during the mapping process.

"While high-density maps generated through multi-electrode mapping provide the most comprehensive and accurate image of the cardiac structures, this process can prove to be time-intensive," said Vias Markides, M.D., director of the Heart Division at Royal Brompton Hospital, London, United Kingdom. "The Confidense Module streamlines the mapping and validation process, which has the potential to reduce overall mapping, annotation and re-annotation time. I'm pleased that continued innovation in this space is enabling us to realize important clinical efficiencies while preserving the critical data and accuracy we have come to rely on from the Carto System."

Multi-electrode mapping allows for the rapid acquisition of a large quantity of data used to generate detailed, high-density maps on the Carto 3 System. Previously, validating the information acquired through multi-electrode mapping required a very detailed manual process, but the Confidense Module enhances the 3-D mapping experience with several novel features that simplify and accelerate map creation while maintaining accuracy.

The module also:

  • Provides a real-time assessment of whether catheter electrodes are in proximity with heart tissue while selectively utilizing the points closest to the tissue to generate a high-quality 3-D map;
  • Enhances the consistency of quality data acquisition with an advanced algorithm; and
  • Accurately identifies and quickly evaluates points whose timing is judged to be inconsistent in comparison with neighboring points, which are then flagged and immediately brought to the physician's attention.

 

The Confidense Module is CE Marked in Europe and received U.S. Food and Drug Administration (FDA) 510(k) clearance in the United States.

For more information: www.biosensewebster.com

Related Content

Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
Overlay Init